BRENTWOOD, Calif.- - (BUSINESS WIRE)- - Halt Medical, Inc., a secretly held therapeutic gadget organization which grows insignificantly obtrusive, uterine saving answers for ladies who experience the ill effects of symptomatic fibroids, today declared five modified works on the Acessa System will be displayed orally at the 45th Annual Global Congress on Minimally Invasive Gynecology Meeting, being held November 14-18 in Orlando, Florida.
End Medical Inc declares platform presentations at 45th Annual AAGL Global Congress on Minimally Invasive Gynecology
Tweet this
New Instrumentation or Technology on November 16, 2016 from 12:10 PM - 12:48 PM
Dr. Nicole Williams, Gynecology Institute of Chicago, will display two modified works on post-showcase results and ultrasound assessments after radiofrequency removal of symptomatic uterine fibroids
Dr. Keith Isaacson, Director of Minimally Invasive Gynecology at Newton-Wellesley, will introduce clinical results at three years from the LUSTOR Study, a randomized controlled clinical trial of Acessa versus Myomectomy
Dr. Kelly Braun, Associate Professor Augusta University, will show on ten specialists' initial involvement and capability utilizing the original Acessa System in only two to five methods
New Instrumentation or Technology on November 17, 2016 from 2:47 PM - 2:53 PM
Dr. Bruce Lee, designer of the Acessa System, will show on the sheltered and powerful utilization of radiofrequency removal of uterine fibroids in symptomatic patients with uteri 15-weeks gestational size and more noteworthy
Dr. Nicole Williams at the Gynecology Institute of Chicago expressed, "I have treated well more than 100 patients with Acessa and have been exceptionally happy with the outcomes. Similarly essential, Acessa has given the patients in my work on confronting hysterectomy an option. Much of the time, there is no compelling reason to evacuate the uterus. Acessa permits me to treat the fundamental issue (the fibroids), while leaving a generally solid organ unharmed." This week, Dr. Williams will share true, post-agent results after the treatment of 81 ladies with symptomatic fibroids.
What are uterine fibroids?
Uterine fibroids are generous, strong tumors in a lady's uterus that can bring about substantial dying, excruciating periods, weight, and distension of the guts [1]. No less than 70% of ladies in the U.S. will create fibroids by the age of 50, with the pervasiveness considerably higher among African-American ladies [2]. Thus, they remain a noteworthy ladies' medical problem with huge financial and conceptive effect. The NIH has established that immediate medicinal services costs for the surgical treatment of fibroids are more than $2.1 billion every year [3]. In an across the country inpatient test, over a large portion of a million ladies experienced hysterectomy for considerate gynecologic conditions [4] and the American Congress of Obstetricians and Gynecologists (ACOG) states that 39% of all hysterectomies are because of fibroids [5]. After some time, patients and gynecologists are swinging to less obtrusive systems, and laparoscopic alternatives are turning out to be more prevalent [6].
The Acessa System is a negligibly intrusive, uterine rationing, laparoscopic technique that conveys radiofrequency vitality to devastate the fibroids. After treatment, the fibroid is reabsorbed by the encompassing tissue. The methodology permits the specialist to treat just the fibroids, while safeguarding ordinary capacity of the uterus. Patients commonly go home that day with insignificant distress, and appreciate a quick come back to ordinary exercises.
About Halt Medical, Inc. – The Company is centered around building up another standard of administer to ladies with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE check for use in percutaneous, laparoscopic coagulation and removal of delicate tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound direction. The Company is situated in Brentwood, CA. For data about the Acessa System, please visit www.acessaprocedure.com.
REFERENCES:
1. www.womenshealth.gov
2. Baird DD et al. High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. Am J Obstet Gynecol 2003; 188 (1):100-107.
3. National Institutes of Health reality sheet: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=50
4. Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Across the nation Use of Laparoscopic Hysterectomy Compared with Abdominal and Vaginal Approaches. Obstet Gynecol 2009;114(5):1041-1048.
5. www.ACOG.org. 2011 Women's Health Stats and Facts: p.18.
6. Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Execution of Advanced Laparoscopic Surgery in Gynecology: National Overview of Trends. J Minim Invasive Gynecol 2010;17(4):487-492.
End Medical Inc declares platform presentations at 45th Annual AAGL Global Congress on Minimally Invasive Gynecology
Tweet this
New Instrumentation or Technology on November 16, 2016 from 12:10 PM - 12:48 PM
Dr. Nicole Williams, Gynecology Institute of Chicago, will display two modified works on post-showcase results and ultrasound assessments after radiofrequency removal of symptomatic uterine fibroids
Dr. Keith Isaacson, Director of Minimally Invasive Gynecology at Newton-Wellesley, will introduce clinical results at three years from the LUSTOR Study, a randomized controlled clinical trial of Acessa versus Myomectomy
Dr. Kelly Braun, Associate Professor Augusta University, will show on ten specialists' initial involvement and capability utilizing the original Acessa System in only two to five methods
New Instrumentation or Technology on November 17, 2016 from 2:47 PM - 2:53 PM
Dr. Bruce Lee, designer of the Acessa System, will show on the sheltered and powerful utilization of radiofrequency removal of uterine fibroids in symptomatic patients with uteri 15-weeks gestational size and more noteworthy
Dr. Nicole Williams at the Gynecology Institute of Chicago expressed, "I have treated well more than 100 patients with Acessa and have been exceptionally happy with the outcomes. Similarly essential, Acessa has given the patients in my work on confronting hysterectomy an option. Much of the time, there is no compelling reason to evacuate the uterus. Acessa permits me to treat the fundamental issue (the fibroids), while leaving a generally solid organ unharmed." This week, Dr. Williams will share true, post-agent results after the treatment of 81 ladies with symptomatic fibroids.
What are uterine fibroids?
Uterine fibroids are generous, strong tumors in a lady's uterus that can bring about substantial dying, excruciating periods, weight, and distension of the guts [1]. No less than 70% of ladies in the U.S. will create fibroids by the age of 50, with the pervasiveness considerably higher among African-American ladies [2]. Thus, they remain a noteworthy ladies' medical problem with huge financial and conceptive effect. The NIH has established that immediate medicinal services costs for the surgical treatment of fibroids are more than $2.1 billion every year [3]. In an across the country inpatient test, over a large portion of a million ladies experienced hysterectomy for considerate gynecologic conditions [4] and the American Congress of Obstetricians and Gynecologists (ACOG) states that 39% of all hysterectomies are because of fibroids [5]. After some time, patients and gynecologists are swinging to less obtrusive systems, and laparoscopic alternatives are turning out to be more prevalent [6].
The Acessa System is a negligibly intrusive, uterine rationing, laparoscopic technique that conveys radiofrequency vitality to devastate the fibroids. After treatment, the fibroid is reabsorbed by the encompassing tissue. The methodology permits the specialist to treat just the fibroids, while safeguarding ordinary capacity of the uterus. Patients commonly go home that day with insignificant distress, and appreciate a quick come back to ordinary exercises.
About Halt Medical, Inc. – The Company is centered around building up another standard of administer to ladies with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE check for use in percutaneous, laparoscopic coagulation and removal of delicate tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound direction. The Company is situated in Brentwood, CA. For data about the Acessa System, please visit www.acessaprocedure.com.
REFERENCES:
1. www.womenshealth.gov
2. Baird DD et al. High Cumulative Incidence of Uterine Leiomyoma in Black and White Women: Ultrasound Evidence. Am J Obstet Gynecol 2003; 188 (1):100-107.
3. National Institutes of Health reality sheet: http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=50
4. Jacoby VL, Autry A, Jacobson G, Domush R, Nakagawa S, Jacoby A. Across the nation Use of Laparoscopic Hysterectomy Compared with Abdominal and Vaginal Approaches. Obstet Gynecol 2009;114(5):1041-1048.
5. www.ACOG.org. 2011 Women's Health Stats and Facts: p.18.
6. Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Execution of Advanced Laparoscopic Surgery in Gynecology: National Overview of Trends. J Minim Invasive Gynecol 2010;17(4):487-492.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.